Edition:
United States

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

6.72CAD
3:59pm EST
Change (% chg)

$0.16 (+2.44%)
Prev Close
$6.56
Open
$6.52
Day's High
$6.77
Day's Low
$6.49
Volume
61,294
Avg. Vol
54,739
52-wk High
$14.17
52-wk Low
$2.75

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

Beta: 3.44
Market Cap(Mil.): $549.06
Shares Outstanding(Mil.): 83.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.71 15.46
EPS (TTM): -- -- --
ROI: -- -10.20 11.85
ROE: -- -36.19 15.83

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

Nov 14 2017

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

Oct 23 2017

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

Oct 20 2017

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

Aug 10 2017

BRIEF-Aurinia Pharmaceuticals resolves temporary non-compliance with Nasdaq's audit committee composition rule

* Aurinia resolves temporary non-compliance with Nasdaq's audit committee composition rule Source text for Eikon: Further company coverage:

Jul 12 2017

BRIEF-Aurinia Pharma presents voclosporin remission data

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

Jun 16 2017

Earnings vs. Estimates